yingweiwo
  1. Home
  2. Products
  3. Signaling Pathways
  4. Immunology / Inflammation
  5. PD-1 PD-L1

PD-1 PD-L1

PD-1 PD-L1

A cell surface receptor called Programmed Death-1 (PD-1) serves as a T cell checkpoint and is crucial in controlling T cell exhaustion. PDL-1 or PDL-2 engagement with PD-1 causes it to become active. When the PD-1 receptor binds to its ligands, PD-L1 and PD-L2, which are expressed on cancer cells and antigen-presenting cells, it sends inhibitory checkpoint signals to activated T cells. This suppresses T-cell effector function and allows tumor immune evasion. An appealing approach for tumor immunotherapy is to block the programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) pathway.

Activated T cells, B cells, monocytes, dendritic cells, regulatory T cells, and natural killer T cells all express PD-1. It belongs to a group of immunoglobulin domain (Ig) co-receptors that affect how the T cell receptor responds when activated by an antigen-presenting cell (APC) or an infected target cell. In contrast to PD-L2, which is only and inducibly expressed on professional APCs, PD-L1 is widely expressed and constitutively on both hematopoietic and nonhematopoietic cells, including naive T and B cells, vascular endothelial cells, and pancreatic islet cells.

PD-1 PD-L1 related products

Structure Cat No. Product Name CAS No. Product Description
(2R,3S)-PD-1/PD-L1-IN-38 V84644 (2R,3S)-PD-1/PD-L1-IN-38
(D)-PPA 1 V75249 (D)-PPA 1 1620813-53-7 (D)-PPA 1 is a hydrolytic D-peptide antagonist.
ASC-69 (APY69) V75245 ASC-69 (APY69) 1216665-50-7 ASC-69 (APY69) is a potent small molecule inhibitor of PD-1/PD-L1.
Benmelstobart V74276 Benmelstobart 2303884-58-2 This product is discontinued due to commercial reason. Benmelstobart is an IgG1κ antibody targeting PD-L1/CD274, developed from mice.
BMS-1001 Sodium salt V2191 BMS-1001 Sodium salt BMS-1001 is a novel and potent PD-1/PD-L1 interaction inhibitor.
BMS-1166盐酸 V3826 BMS-1166 HCl 2113650-05-6 BMS-1166 HCl, the hydrochloride salt ofBMS1166, is a novel and potent small molecule inhibitor of the PD-1/PD-L1 PPI/protein protein interaction with anticancer and immunomodulatory activity.
BMSpep-57 V75251 BMSpep-57 1629655-80-6 BMSpep-57 is a potent macrocyclic peptide inhibitor that can suppress PD-1/PD-L1 interaction with IC50 of 7.68 nM.
CA-170 V3254 CA-170 1673534-76-3 CA-170 (also known as AUPM170 or PD-1-IN-1) is a first-in-class, potent and orally available small molecule inhibitor of the immune checkpoint regulatory proteins PD-L1 (programmed cell death ligand-1), PD-L2 and VISTA (V-domain immunoglobulin (Ig) suppressor of T-cell activation (programmed death 1 homolog; PD-1H).
Eciskafusp alfa V74275 Eciskafusp alfa 2649758-52-9 Eciskafusp alfa is a programmed cell death 1 (PDCD1, best known as PD-1) cis-targeting IL2v immune cytokine.
Evixapodlin V3348 Evixapodlin 2374856-75-2 Evixapodlin (GS-4224) is an inhibitor (blocker/antagonist) of human PD-1/PD-L1 protein/protein interaction with IC50 of 0.213 nM.
Human membrane-bound PD-L1 polypeptide V75241 Human membrane-bound PD-L1 polypeptide 1831010-13-9 Human membrane-bound PD-L1 polypeptide can serve as an antigen to induce the production of PD-L1 antibodies.
Human PD-L1 inhibitor I V75232 Human PD-L1 inhibitor I 2135542-86-6 Human PD-L1 inhibitor I is an hPD-1 peptide ligand with a Kd of 3.39 μM.
Human PD-L1 inhibitor II V75235 Human PD-L1 inhibitor II 2135542-85-5 Human PD-L1 inhibitor II is a potent PD-L1 inhibitor (antagonist) with anti-cancer activity.
Human PD-L1 inhibitor III V74274 Human PD-L1 inhibitor III 2135542-84-4 Human PD-L1 inhibitor III is an inhibitor (blocker/antagonist) of human PD-L1.
Human PD-L1 inhibitor IV V75216 Human PD-L1 inhibitor IV 2135542-83-3 Human PD-L1 inhibitor IV is a competitive human PD-1 protein inhibitor (antagonist) with a Kd of 1.38 μM, which can inhibit the binding of human PD-1/PD-L1.
Human PD-L1 inhibitor V V75233 Human PD-L1 inhibitor V 2815311-61-4 Human PD-L1 inhibitor V is a human PD-1 protein binding peptide with a Kd of 3.32 μM, which can inhibit the binding of human PD-1/PD-L1.
INCB086550 V4418 INCB086550 2230911-59-6 INCB-086550 (INCB-086550) is a novel, investigational and selective small moleculePD-1/PD-L1 inhibitor based on the biphenyl scaffold core structure first disclosed by BMS company.
Latika fusp (AMG 256) V75238 Latika fusp (AMG 256) 2552814-07-8 Latikafusp (AMG 256) is a bifunctional fusion protein containing an antibody targeting PD-1 and an IL-21 mutant protein designed to provide IL-21 pathway stimulation to PD-1+ cells.
LH1306 V84000 LH1306 2182653-84-3
PD-1-IN-24 V75207 PD-1-IN-24 2360909-50-6 PD-1-IN-24 (compound 1) is an orally bioactive inhibitor of PD-1.
Contact Us
Tel: 1-708-310-1919 Fax: 1-708-557-7486 Email: sales@invivochem.com Frequently Asked Questions
Subscribe to our E-newsletter
Name
E-mail

Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved

linkedin facebook
Contact Us
Home Product Cart Member